



## Symbicort® (budesonide/formoterol) – Updated indication

- On September 11, 2017, the FDA approved AstraZeneca's **Symbicort (budesonide/formoterol)** for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. Symbicort 160/4.5 is also indicated to reduce exacerbations of COPD. Symbicort 160/4.5 is the only strength indicated for the treatment of COPD.
  - Previously, Symbicort was indicated for the twice daily maintenance treatment of airflow obstruction in patients with COPD including chronic bronchitis and emphysema. Symbicort 160/4.5 is the only strength indicated for the treatment of airflow obstruction in COPD.
  - Symbicort is also indicated for the treatment of asthma in patients 6 years of age and older.
  - Symbicort is not indicated for the relief of acute bronchospasm.
- Symbicort carries a boxed warning for asthma-related death.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.